藥物基因組學(xué)是一份同行評審的期刊，由與這一快速發(fā)展領(lǐng)域密切相關(guān)的研究人員和決策者撰寫評論和報告。主要的目標(biāo)是為社會提供一項(xiàng)基本的資源，使他們能隨時掌握這一令人興奮的領(lǐng)域所有領(lǐng)域的最新發(fā)展。藥物基因組學(xué)關(guān)注與制藥行業(yè)和更廣泛的臨床社區(qū)最直接相關(guān)的方面，包括:新藥物基因組計劃的出現(xiàn)及其對研發(fā)和監(jiān)管戰(zhàn)略的影響;獲取和利用基因組信息的新興技術(shù);綜述基因分型和特定治療領(lǐng)域的臨床數(shù)據(jù);開發(fā)新的診斷產(chǎn)品和策略。藥物基因組學(xué)是評論和分析的主要來源，為您帶來來自該領(lǐng)域的企業(yè)和學(xué)術(shù)意見領(lǐng)袖的最高質(zhì)量的專家分析。

Pharmacogenomics is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics focuses on those aspects that have the most direct relevance to the pharmaceutical industry and wider clinical community, including: The emergence of new pharmacogenomic initiatives and their impact on R&D and regulatory strategies; Emerging technologies for accessing and exploiting genomic information; Reviews of genotyping and clinical data in particular therapeutic areas; Development of novel diagnostic products and strategies. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.